GlassScriptPhysician profile
Bob Joe Schank
NPI 1417243882
$7,283.94
in general payments reported to CMS, 2019-2025
35 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,300 · 2020: $197 · 2021: $13.92 · 2022: $1,152 · 2023: $1,615 · 2024: $1,275 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,621.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,044.85 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $974.66 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $931.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $891.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $583.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.54 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $539.45 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $239.16 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $186.19 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $168.45 | 2022-2024 | Rexulti |
| Allergan, INC. | $114.79 | 2019 | |
| Aimmune Therapeutics, INC. | $107.48 | 2024-2025 | Zenpep |
| Abbott Laboratories | $82.98 | 2024-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $75.67 | 2023-2024 | Quviviq |
| Dexcom, INC. | $75.20 | 2022-2023 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $69.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $66.24 | 2019-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Amgen INC. | $65.21 | 2019-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $64.32 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $64.22 | 2019 | |
| Nestle Healthcare Nutrition INC. | $36.48 | 2022 | |
| Medtronic, INC. | $36.41 | 2025 | Inceptiv |
| E.R. Squibb & Sons, L.L.C. | $36.35 | 2022-2023 | Eliquis |
| Organon LLC | $31.93 | 2022-2023 | Nexplanon |
| Janssen Pharmaceuticals, INC | $31.40 | 2019-2020 | |
| Medtronic Minimed, INC. | $30.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.25 | 2022 | |
| Edwards Lifesciences Corporation | $26.25 | 2022 | |
| Exeltis, USA INC. | $18.70 | 2025 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $18.08 | 2023 | Trintellix |
| Hologic Sales and Service, LLC | $15.46 | 2023 | Aptima |
| Antares Pharma, INC. | $14.79 | 2019 | |
| Spr Therapeutics, INC | $14.31 | 2025 | Sprint Pns System |
| Currax Pharmaceuticals LLC | $13.70 | 2024 | Contrave, Onzetra Xsail |
| Kowa Pharmaceuticals America, INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Schank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.